{"classes":[{"categories":[{"measurements":[{"comment":"Median and confidence interval was not estimable due to low number of participants with events.","groupId":"OG000","lowerLimit":"42.1","upperLimit":"NA","value":"NA"},{"comment":"Median and confidence interval was not estimable due to low number of participants with events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"543"},{"groupId":"OG001","value":"528"}],"units":"Participants"}],"description":"DOCR per IRF in participants with CR was the time between first documentation of CR and PD as determined by an IRF. PD was defined as any new lesion or increase by \\>=50% of previously involved sites from nadir. CR was defined as disappearance of all evidence of disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Brentuximab vedotin 1.2 milligram per kilogram (mg/kg), infusion, intravenously over 30-minutes plus doxorubicin 25 milligram per square meter (mg/m\\^2), vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles. Brentuximab vedotin was administered within approximately 1 hour after completion of AVD.","id":"OG000","title":"A+AVD"},{"description":"Doxorubicin 25 mg/m\\^2, bleomycin 10 units per square meter (units/m\\^2), vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles.","id":"OG001","title":"ABVD"}],"paramType":"MEDIAN","populationDescription":"The ITT population included all participants randomized to treatment. The ITT population where participants achieved CR.","reportingStatus":"POSTED","timeFrame":"From first documentation of CR until PD (approximately 4 years)","title":"Duration of Complete Remission (DOCR) Per IRF","type":"SECONDARY","unitOfMeasure":"months"}